## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

Claims 1-26 (canceled)

Claim 27 (currently amended): A method for enhancing efficacy of a chemotherapeutic agent for a cancer cell, said method comprising administering systemically to a subject in need thereof an effective amount of hyaluronan and said chemotherapeutic agent, wherein the hyaluronan has a ~~molecular weight between 400,000 and 900,000~~ modal molecular weight of 890,000 Da.

Claims 28-29 (canceled)

Claim 30 (currently amended): The method according to Claim [[28]] 27, wherein the hyaluronan has a molecular weight of 890,000 Da.

Claim 31 (canceled)

Claim 32 (currently amended): The method according to Claim [[28]] 27, wherein the chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide or combinations thereof.

Claim 33 (currently amended): A method for enhancing efficacy of a chemotherapeutic agent for a cancer cell, said method comprising administering systemically to a subject in need thereof an effective amount of a composition consisting essentially of hyaluronan and said chemotherapeutic agent, wherein the hyaluronan has a ~~molecular weight between 400,000 and 900,000~~ modal molecular weight of 890,000 Da.

Claims 34-35 (canceled)

Claim 36 (currently amended): The method according to Claim [[34]] 33, wherein the hyaluronan has a molecular weight of 890,000 Da.

Claim 37 (canceled)

Claim 38 (currently amended): The method according to Claim [[34]] 33, wherein the chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide.

Claim 39 (currently amended): A method for overcoming acquired resistance of cancer cells to a chemotherapeutic agent, said method comprising administering systemically to a subject having said resistant cancer cells a hyaluronan and said chemotherapeutic agent, wherein the hyaluronan has a ~~molecular weight between 400,000 and 900,000~~ modal molecular weight of 890,000 Da.

Claims 40-41 (canceled)

Claim 42 (currently amended): The method according to Claim [[40]] 39, wherein the hyaluronan has a molecular weight of 890,000 Da.

Claim 43 (canceled)

Claim 44 (currently amended): The method according to Claim [[40]] 39, wherein the chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide.

Claim 45 (currently amended): A pharmaceutical composition formulated for systemic administration consisting essentially of [[a]] an anticancer chemotherapeutic agent and hyaluronan, wherein the hyaluronan has a ~~molecular weight between 400,000 and 900,000~~ modal molecular weight of 890,000 Da.

Claims 46-47 (canceled)

Claim 48 (currently amended): The pharmaceutical composition of Claim [[46]] 45, wherein the hyaluronan has a molecular weight of 890,000 Da.

Claim 49 (canceled)

Claim 50 (currently amended): The pharmaceutical composition of Claim [[46]] 45, wherein the chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide.

Claim 51 (currently amended): A pharmaceutical composition formulated for systemic administration comprising [[a]] an anticancer chemotherapeutic agent and hyaluronan having molecular weight of modal molecular weight of 890,000 Da.

Claim 52 (previously presented): The pharmaceutical composition of Claim 51, wherein the hyaluronan has molecular weight 890,000 Da.

Claims 53-56 (canceled)

Claim 57 (new): The method of claim 27, wherein the hyaluronan has a polydispersity of 1.78.

Claim 58 (new): The method of claim 33, wherein the hyaluronan has a polydispersity of 1.78.

Claim 59 (new): The method of claim 27, wherein the hyaluronan and the chemotherapeutic agent are administered intravenously.

Claim 60 (new): The method of claim 33, wherein the hyaluronan and the chemotherapeutic agent are administered intravenously.

Claim 61 (new): The pharmaceutical composition of claim 45, wherein the hyaluronan has a polydispersity of 1.78.

Claim 62 (new): The pharmaceutical composition of claim 45, wherein the hyaluronan and the chemotherapeutic agent are formulated for intravenous administration.